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Honeyandcancerhasasustainableinverserelationship.Carcinogenesisisamultistepprocessandhasmultifactorialcauses.Among
these are low immune status, chronic infection, chronic inﬂammation, chronic non healing ulcers, obesity, and so forth. There is
now a sizeable evidence that honey is a natural immune booster, natural anti-inﬂammatory agent, natural antimicrobial agent,
natural cancer “vaccine,” and natural promoter for healing chronic ulcers and wounds. Though honey has substances of which the
most predominant is a mixture of sugars, which itself is thought to be carcinogenic, it is understandable that its beneﬁcial eﬀect as
anticancer agent raises skeptics. The positive scientiﬁc evidence for anticancer properties of honey is growing. The mechanism on
how honey has anticancer eﬀect is an area of great interest. Among the mechanisms suggested are inhibition of cell proliferation,
induction of apoptosis, and cell-cycle arrest. Honey and cancer has sustainable inverse relationship in the setting of developing
nations where resources for cancer prevention and treatment are limited.
1. Cancer:The GlobalEpidemic
Cancer is a global epidemic. In 2008, it was estimated there
were 12,332,300 cancer cases of which 5.4 million were
in developed countries and 6.7 million were in developing
countries [1] (Figure 1). Over half of the incident cases
occurred in residents of four WHO regions. The world
population increased from 6.1 billion in 2000 to 6.7 billion
in 2008 [2]. The increase in populations was much more
in developing countries than in developed countries. Even if
the age-speciﬁc rates of cancer remain constant, developing
countries would have a higher cancer burden than developed
countries.
Cancer trends are showing upward trends in many
developingcountries[3–5]andamixedpatternindeveloped
countries [6–8]. By 2050, the cancer burden could reach
24 million cases per year worldwide, with 17 million cases
occurring in developing countries [9]. Cancers which are
associated with diet and life style are seen more in developed
countries while cancers which are due to infections are more
in developing countries. According to the World Health
Organization (WHO), death from cancer is expected to
increase to 104% worldwide by 2020.
While the number of total cancer is increasing, the trend
of certain cancers is changing in developed and developing
countries. In developed countries, the trend is declining
[10] since infections by microorganisms are declining and
screening facilities are available. In Singapore, there was an
average annual increase of 3.6% for breast cancers in women
in the 1988–1992 period [11]. In Qatar, there was a 57.1%
riseofcancers1991–2006[12],andinNetherlands,therewas
an increase between 1.9% (females) and 3.4% (males) per
year for oesophageal cancer 1989–2003 [13].
In order to understand the usefulness of honey in cancer,
we need to understand the various factors which could cause
cancer. Carcinogenesis is a multi-step process and has multi-
factorial causes. Development of cancers takes place long
after initiation, promotion, and progression steps (Figure 2)
have taken place. The cellular damage could be by one factor
or multiplicity of these factors. The latter is more frequent.
Cancer development could occur 10–15 years after exposure
to the risk factors.2 Evidence-Based Complementary and Alternative Medicine
(16) Southern Europe (675,000)
(17) Western Europe (950,500)
(18) Australia/New Zealand (117,700)
(19) Melanesia (7,700)
(20) Micronesia (700)
(21) Polynesia (900)
(11) South-Eastern Asia (618,800)
(12) South Central Asia (1,451,700)
(13) Western Asia (225,900)
(14) Eastern Europe (939,500)
(15) Northern Europe (448,700)
∗Region estimates do not sum to worldwide estimate due to calculation method
8
21
6 7
9 17
15
16
3
5
2
4
1
13
12
14
10
11 20
19
18
7
Estimated number of new cancer cases by world area, 2007
Worldwide∗
12,332,300
(1) Eastern Africa (290,100)
(2) Middle Africa (87,800)
(3) Northern Africa (142,100)
(4) Southern Africa (78,100)
(5) Western Africa (166,300) (10) Eastern Asia (3,313,600)
(6) Caribbean (73,500)
(7) Central America (184,800)
(8) South America (733,100)
(9) North America (1,745,400)
Figure 1: Estimated new cancer cases by world areas (source: Global Cancer Facts and Figures 2007).
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Figure 2:Stepsincarcinogenesis. ∗Stepsalteredbyalcoholconsumption(Source:Garroetal.AlcoholHealth&ResearchWorld16(1):81–86,
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1.1.Life-StyleHabits/DiseasesasRiskstoCancerDevelopment.
Cancer is caused by genetic damage in the genome of cells.
This damage is either inherited or acquired throughout
life. The acquired genetic damage is often “self-inﬂicted”
through unhealthy lifestyles. Essentially one-third of cancer
is due to tobacco use, one-third due to dietary and lifestyle
factors, and one-ﬁfth due to infections. Other factors include
chemical carcinogens, environmental pollutants, and alcohol
(Figure 3). In the developing countries, cancers caused by
infections by microorganisms such as cervical (by human
papilloma virus) [14], liver (by hepatitis viruses) [15],
nasopharynx (by Epstein-Barr virus) [16], and stomach (by
Helicobacter pylori)[ 17] are more common than those in
developed countries [18]. While cancers of the prostate,
breasts, and colorectal are clearly more prevalent in devel-
oped than developing countries, the distinction is not very
apparent as that for cancer of the lung which is as prevalent
as that in more or less developed nations. Except for breast
cancers, the top 5 cancers in males and females of developing
nations are due to life-styles or infections [18].
1.1.1. Smoking and Tobacco Use. Association of cancer to
cigarette smoking is beyond doubt. The prevalence of smok-
ing is higher in developing than that in developed countries
[19]. Smoking is associated with a number of cancers such
as larynx, bladder, breasts, oesophagus, and cervix. While in
developed countries the prevalence of smoking is decreasing
[20], the scenario is the reverse in developing countries. The
initiation and the inﬂuence to start smoking are similar to
those in developed countries [21]. Smoking increases the
risk of colorectal carcinomas by 43% [22]. Ever-smokers
were associated with an 8.8-fold increased risk of colorectal
cancers (95% conﬁdence interval, 1.7–44.9) when fed on
well-doneredmeatdietiftheyhaveNAT2andCYP1A2rapid
phenotypes [23]. No similar association was found in never-
smokers [23].
1.1.2. Obesity and Physical Inactivity. Obese subjects have
an approximately 1.5–3.5-fold increased risk of developing
cancerscomparedwithnormal-weightsubjects[24].Obesity
is associated in a number of cancers [25, 26] particularly
endometrium [27, 28], breasts [29, 30], and colorectal
cancers [31]. Adipocytes have the ability to enhance the
proliferation of colon cancer cells in vitro [32]. The trend of
prevalence of overweight/obesity is rising in many developed
and developing countries [33]. In a study conducted in 2005
[34] in the Kota Bharu district in the state of Kelantan
Malaysia, the overall prevalence of overweight/obesity was
49.1% [34], much higher than the ﬁgure reported earlier
in 1996 [35]. In this community, the rise of cancer is
exponential in the period from year 2002 to 2007 (143.6%
increment) compared to the previous 5-year period of 1996–
2001 [36].
Obesity is not a social problem but a disease. The greatest
risk is for obese persons who are also diabetic, particular
thosewhosebodymassindexisabove35kg/m2.Theincrease
in risk is by 93-fold in women and by 42-fold in men [37].
1.1.3. Diabetes Particularly Type 2 as Risk for Cancer Devel-
opment. Obesity is closely related with diabetes [38]. A
community that has high prevalence of obesity also has
high prevalence of diabetes [36]. In Kelantan, Malaysia, the
prevalence of diabetes in 1999 was 10.5%, and impaired
glucose tolerance was 16.5% [39]. Kelantan is ranked highest
in prevalence of diabetes in Malaysia in which the overall
national prevalence is 8.3% [40], thus it was not a surprise
to see a rapid rise of cancer prevalence in the state [36].
According to a review on diabetes, the WHO has estimated
that, by 2030, there would be 2.48 million diabetics in
Malaysia, a jump of 164% from 0.94 million in 2002 [41].
One of the most common cancers noted in community that
has high diabetics and obesity is colorectal cancer [42–45].
In a study of 138 colorectal cancers (CRC) seen in
Hospital Universiti Sains Malaysia, 47.8% had metabolic
diseases, of which 13.8% were diabetes type 2 [42]. Those
diabetics with CRC often have distal cancers [42].
1.2. Chronic Infections as Risk for Cancer Development. There
are a number of microorganisms which could cause cancer.
Common viruses causing cancers [46] are Epstein-Barr virus
(EBV) [47] (nasopharyngeal carcinomas), human papilloma
virus (cervical cancers and other squamous cancers) and
Hepatitis B viruses (liver cancers). Viruses are oncogenic
a f t e rl o n gp e r i o do fl a t e n c y[ 48].
Bacteriawhichhasbeenstudiedtohaveassociationswith
cancer are Helicobacter pylori infections (stomach cancer)
[17], Ureaplasma urealyticum (prostate cancer) [49], and
chronic typhoid carrier (gall bladder cancer) [50]. Chronic
fungi infections have also been studied to be associated with
cancer [51]. Parasites such as Schistosoma haematobium are
associated with carcinoma of the urinary bladder; liver ﬂukes
Opisthorchis viverrini and Clonorchis sinensis associated with
cholangiocarcinoma and hepatocellular carcinoma. There
are three main mechanisms by which infections can cause
cancer.Theyappeartoinvolveinitiationaswellaspromotion
of carcinogenesis [52]. Persistent infection within host
induces chronic inﬂammation accompanied by formation
of reactive oxygen and nitrogen species (ROS and RNOS)
[52]. ROS and RNOS have the potential to damage DNA,
proteins, and cell membranes. Chronic inﬂammation often
results in repeated cycles of cell damage leading to abnormal
cell proliferation [53]. DNA damage promotes the growth
of malignant cells. Secondly, infectious agents may directly
transform cells, by inserting active oncogenes into the
host genome, inhibiting tumour suppressors or stimulating
mitosis [52]. Thirdly, infectious agents, such as human
immunodeﬁciency virus (HIV), may induce immunosup-
pression [52].
2.Low ImmuneStatusas Risk of
Cancer Development
2.1. Cancer and Aging. The most important change that
would occur in the world population in the next 50 years is
the change in the proportion of elderly people (more than
65 years): 7% in 2000 to 16% in 2050 [54]. Many cancers4 Evidence-Based Complementary and Alternative Medicine
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Figure 3: The acquired risk factors of cancer development.
are associated with aging. Although age per se is not an
important determinant of cancer risk, it implies prolonged
exposure to carcinogen [55]. By the year 2050, 27 million
people are projected to have cancer. More than half of the
estimated number will be residents of developing countries
[54]. Aging is also associated with reduced immune system.
2.2. Low Immune Status due to Chronic Diseases. Patients
who have low immune system are at risk for cancer
development. This explains why diabetics are more at risk
than non-diabetics to get epithelial cancers. HIV patients are
at risk to develop epithelial and nonepithelial cancers. These
personsarealsoatrisktodevelopmultiplechronicinfections
implying the multiplicity in cancer genesis. Patients with
autoimmune diseases are also at risk to develop cancers such
as colorectal carcinomas in ulcerative colitis and Crohn’s
disease and thyroid cancer in autoimmune thyroiditis.
2.3. Chronic Ulcers and Wounds. Chronic ulcers have risk to
develop cancer. The most common is Marjolin’s ulcer [56],
and they are common in developing nations especially in
rural areas with poor living conditions [57]. This risk factor
isrelatedtochronicinfectionsasmostifnotallchroniculcers
are not healing because of persistent infections.
3.What Is HoneyandWhy Is ItUseful against
Cancer?(SeeFigure4)
Honey is known for centuries for its medicinal and health-
promoting properties. It contains various kinds of phyto-
chemicals with high phenolic and ﬂavonoid content which
contribute to its high antioxidant activity [58–60]. Agent
that has strong antioxidant property may have the potential
to prevent the development of cancer as free radicals
and oxidative stress play a signiﬁcant role in inducing
the formation of cancers [61]. Phytochemicals available in
honey could be narrowed down into phenolic acids and
polyphenols.Variantsofpolyphenolsinhoneywerereported
to have antiproliferative property against several types of
cancer [62].
4 .H o neyA saN at uralI m m uneBoo s t e r
Honey stimulates inﬂammatory cytokine production from
monocytes [63] .M a n u k a ,p a s t u r e ,a n dj e l l yb u s hh o n e y
were found to signiﬁcantly increase TNF-α,I L - 1 β,a n dI L -
6 release from MM6 cells (and human monocytes) when
compared with untreated and artiﬁcial honey-treated cells
(P<0.001) [63]. A 5.8 kDa component of manuka honey
was found to stimulate cytokine production from immune
cells via TLR4 [64]. Honey stimulates antibody production
during primary and secondary immune responses against
thymus-dependent and thymus-independent antigens in
mice injected with sheep red blood cells and E. coli antigen
[65]. Consumption of 80g daily of natural honey for 21
daysshowedthatprostaglandinlevelscomparedwithnormal
subjects were elevated in patient with AIDS [66]. Natural
honey has been shown to decrease prostaglandin level,
elevated NO production in patients with a long history
of AIDS [66]. It was reported that oral intake of honey
augments antibody productions in primary and secondary
immune responses against thymus-dependent and thymus-
independent antigens [67].
These studies suggest that daily consumption of honey
improves one’s immune system.
5.Honey As NaturalAnti-InﬂammatoryAgent
In routine everyday life, our cells may be injured by irritants
from outside or within our bodies (by microbes or nonmi-
crobes). Cellular/molecular injuries result in inﬂammatoryEvidence-Based Complementary and Alternative Medicine 5
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Figure 4: The inverse relationship of honey and cancer.
response, the body defense mechanisms in trying to rid
of the irritants. In general inﬂammatory responses are
beneﬁcial and protective to us, but at times, inﬂammatory
responses are detrimental to health. Honey is a potent anti-
inﬂammatory agent. Infants suﬀering from diaper dermatitis
improved signiﬁcantly after topical application of a mixture
containing honey, olive oil, and beeswax after 7 days [68].
Honey provides signiﬁcant symptom relief of cough in
children with an upper respiratory tract infection (URTI)
[69]. It has been shown to be eﬀective in management
of dermatitis and Psoriasis vulgaris [70]. Eight out of 10
patients with dermatitis and ﬁve of eight patients with
psoriasis showed signiﬁcant improvement after 2 weeks on
honey-based ointment [70]. Honey at dilutions of up to
1:8 reduced bacterial adherence from 25.6 ± 6.5 (control)
to 6.7 ± 3.3 bacteria per epithelial cell (P<0.001) in
vitro [71]. Volunteers who chewed “honey leather” showed
that there were statistically highly signiﬁcant reductions in
mean plaque scores (0.99 reduced to 0.65; P = 0.001)
in the manuka honey group compared to the control
group suggesting a potential therapeutic role for honey for
gingivitis, periodontal disease [72], mouth ulcers, and other
problems of oral health [73].
A case report of a patient who had chronic dystrophic
epidermolysis bullosa (EB) for 20 years healed with honey
impregnated dressing in 15 weeks [74] after conventional
dressings and creams failed. This illustrates the usefulness of
honeyasananti-inﬂammatory agent.Chronic inﬂammatory
process has risk of cancer development.
6.Honey As NaturalAntimicrobials
Everyday we are exposed to all kinds of microbial insults
from bacteria, viruses, parasites, and fungi. Honey is a
potent natural antimicrobial. The most common infections
humans get are from staphylococcal infection. Antibacterial
eﬀect of honey is extensively studied. The bactericidal
mechanismisthroughdisturbanceincelldivisionmachinery
[75]. The minimum inhibitory concentration (MIC) for
Staphylococcus aureus by A. mellifera honey ranged from
126.23to185.70mgml−1 [76].Honeyisalsoeﬀectiveagainst
coagulase-negative staphylococci [77]. Local application of
raw honey on infected wounds reduced signs of acute
inﬂammation [78], thus alleviating symptoms. Antimicro-
bial activity of honey is stronger in acidic media than in
neutral or alkaline media [78]. The potency of honey is
comparable to some local antibiotics. Honey application
into infective conjunctivitis reduced redness, swelling, pus
discharge, and time for eradication of bacterial infections
[78]. When honey is used together with antibiotics, gen-
tamycin, it enhances anti-Staphylococcus aureus activity, by
22%[79].Whenhoneyisaddedtobacterialculturemedium,
the appearance of microbial growth on the culture plates is
delayed [80]. Mycobacteria did not grow in culture media
containing 10% and 20% honey while it grew in culture
media containing 5%, 2.5%, and 1% honey, suggesting that
honey could be an ideal antimycobacterial agent [81]a t
certain concentrations.6 Evidence-Based Complementary and Alternative Medicine
Honey is also eﬀective in killing hardy bacteria such
as Pseudomonas aeruginosa (PA) and could lead to a new
approach in treating refractory chronic rhinosinusitis [82].
Daily consumption of honey reduces risk of chronic infec-
tions by microorganisms. Chronic infections have risk for
cancer development.
There are three main mechanisms by which infections
can cause cancer. They appear to involve initiation as well
as promotion of carcinogenesis [52]. Persistent infection
within host induces chronic inﬂammation accompanied by
formation of reactive oxygen and nitrogen species (ROS and
RNOS) [52]. ROS and RNOS have the potential to damage
DNA, proteins, and cell membranes. Chronic inﬂammation
often results in repeated cycles of cell damage leading to
abnormal cell proliferation [53]. DNA damage promotes
the growth of malignant cells. Secondly, infectious agents
may directly transform cells, by inserting active oncogenes
into the host genome, inhibiting tumour suppressors [52].
Thirdly, infectious agents, such as human immunodeﬁciency
virus (HIV), may induce immunosuppression [52].
The eﬀectiveness of honey is best when used at room
temperature. Heating honey to 80 degrees for 1 hour
decreased antimicrobial activity of both new and stored
honey. Storage of honey for 5 years decreased its antimi-
crobial activity, while ultraviolet light exposure increased its
activity against some of microorganisms [78].
Honey also has been shown to have antiviral properties.
In a comparative study topical application of honey was
found to be better than acyclovir treatment on patients with
recurrentherpeticlesions[83].Twocasesoflabialherpesand
onecaseofgenitalherpesremittedcompletelywiththeuseof
honey while none with acyclovir treatment [83].
7 .H o n eyA sP o s s ib l eA g e n tf o r
Controlling Obesity
Obese individuals are at risk to develop cancer. There is
a close link among obesity, a state of chronic low-level
inﬂammation, and oxidative stress [84]. Obese subjects have
an approximately 1.5–3.5-fold increased risk of develop-
ing cancers compared with normal-weight subjects [24–
26] particularly endometrium [27, 28], breasts [29, 30],
and colorectal cancers [31]. Adipocytes have the ability to
enhance the proliferation of colon cancer cells in vitro [32].
The greatest risk is for obese persons who are also diabetic,
particularly those whose body mass index is above 35kg/m2.
The increase in risk is by 93-fold in women and by 42-fold
in men [37]. One of the most common cancers noted in
community that has high diabetics and obesity is colorectal
cancer [42–45].
In a clinical study on 55 overweight or obese patients, the
controlgroup(17subjects)received70gofsucrosedailyfora
maximum of 30 days and patients in the experimental group
(38 subjects) received 70g of natural honey for the same
period. Results showed that honey caused a mild reduction
in body weight (1.3%) and body fat (1.1%) [85]. Beneﬁcial
eﬀect of honey on obesity is not well established thus far.
8. Honey as“Fixer”for Chronic
UlcersandWounds
Increasing numbers of antibiotic-resistant bacteria has made
simple wounds become chronic and non-healing and as
such honey provides alternative treatment options [86].
Honey absorbs exudates released in wounds and devitalized
tissue [87]. Honey is eﬀective in recalcitrant surgical wounds
[88]. It increases the rate of healing by stimulation of
angiogenesis, granulation, and epithelialization, making skin
grafting unnecessary and giving excellent cosmetic results
[89].Inarandomized controltrial,Manukahoneyimproved
wound healing in patients with sloughy venous leg ulcers
[90]. Honey was shown to eradicate MRSA (Methylene
resistant Staphylococcus aureus) infection in 70% of chronic
venous ulcers [91]. Honey is acidic and chronic non healing
wounds have an elevated alkaline environment. Manuka
honey dressings is associated with a statistically signiﬁcant
decrease in wound pH [92] .A v a i l a b l ee v i d e n c ei nm e t a -
analysis studies indicates markedly greater eﬃcacy of honey
compared with alternative dressings for superﬁcial or partial
thickness burns [93]. Honey is an inexpensive moist dressing
with antibacterial and tissue-healing properties suitable for
diabetic foot [94]. The average cost of treatment per patient
using honey dressing is much cheaper with conventional
dressing [95].
9.Honey As NaturalCancer“Vaccine”
Synthetic vaccines like BCG or polio vaccine work by
preventing vaccinated subjects from contracting tuberculosis
and poliomyelitis. Honey has the element of a “natural
cancer vaccine” as it can reduce chronic inﬂammatory
processes, improve immune status, reduce infections by
hardy organisms and so forth. Some simple and polyphenols
foundinhoney,namely,caﬀeicacid(CA),caﬀeicacidphenyl
esters (CAPE), chrysin (CR), galangin (GA), quercetin
(QU), kaempferol (KP), acacetin (AC), pinocembrin (PC),
pinobanksin (PB), and apigenin (AP), have evolved as
promising pharmacological agents in prevention and treat-
ment of cancer [62]. The antioxidant activity of Trigona
carbonaria honey from Australia is high at 233.96± 50.95
microM Trolox equivalents [96]. The antioxidant activity
of four honey samples from diﬀerent ﬂoral sources showed
high antioxidant properties tested by diﬀerent essay methods
[97]. Dark honey had higher phenolic compounds and
antioxidant activity than clear honey [98]. The amino acid
composition of honey is an indicator of the toxic radical
scavenging capacity [99].
10. Honey as PotentialUse in “Cancer Therapy”
Honey may provide the basis for the development of
novel therapeutics for patients with cancer and cancer-
related tumors. Jungle honey fragments were shown to have
chemotactic induction for neutrophils and reactive oxygen
species (ROS), proving its antitumor activity [67]. Recent
studiesonhumanbreast[100],cervical[100],oral[101],andEvidence-Based Complementary and Alternative Medicine 7
osteosarcoma [101] cancer cell lines using Malaysian jungle
honeyshowedsigniﬁcantanticanceractivity.Honeyhasbeen
shown to have antineoplastic activity in an experimental
bladder model in vivo and in vitro [102].
Honey is rich in ﬂavonoids [62, 103]. Flavanoids have
created a lot of interests among researchers because of its
anticancer properties. The mechanisms suggested are rather
diverse such as various signaling pathways [104], including
stimulation of TNF-alpha (tumor necrosis factor-alpha)
release [105], inhibition of cell proliferation, induction
of apoptosis [106], and cell cycle arrest [107]a sw e l la s
inhibition of lipoprotein oxidation [108]. Honey is thought
to mediate these beneﬁcial eﬀects due to its major com-
ponents such as chrysin [104] and other ﬂavonoids [109].
These diﬀerences are explainable as honeys are of various
ﬂoral sources, and each ﬂoral source may exhibit diﬀerent
active compounds. Though honey has other substances
of which the most predominant are a mixture of sugars
(fructose, glucose, maltose, and sucrose) [110] which itself
is carcinogenic [111], it is understandable that its beneﬁcial
eﬀect on cancer raises skeptics. The mechanism on how
honey has anti-cancer eﬀe c ti sa na r e ao fg r e a ti n t e r e s t
recently. The eﬀects of honeys on hormone-dependent
cancers such as breast, endometrial, and prostate cancer and
tumors remain largely unknown. There is a lot we can learn
from nature [112]. For example, phytochemicals, such as
genistein, lycopene, curcumin, epigallocatechin-gallate, and
resveratrol have been studied to be used for treatment of
prostate cancer [113]. Phytoestrogens constitute a group of
plant-derived isoﬂavones and ﬂavonoids, and honey belongs
to plant phytoestrogen [112, 114].
11. Conclusion
There is now a sizeable evidence that honey is a natural
immune booster, natural anti-inﬂammatory agent, natural
antimicrobial agent, natural cancer “vaccine,” and natural
promoter for healing chronic ulcers and wounds; some of
the risk factors for cancer development. Bee farming is a
lucrativebusiness.Honeyandcancerhavesustainableinverse
relationship in the setting of developing nations where
resources for cancer prevention and treatment are limited.
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